Slay those symptoms: How some giloy can help amid COVID-19 downtoearth.org.in - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from downtoearth.org.in Daily Mail and Mail on Sunday newspapers.
Free Ayush-64 drug for positive patients
Free Ayush-64 drug for positive patients
BySupriya DedgaonkarSupriya Dedgaonkar / Updated: May 13, 2021, 06:00 IST
Distribution of the kits will be done from today; ideal for those with mild to moderate symptoms
In order to help COVID-19 patients with mild and moderate symptoms, the availability of
Ayush-64, an ayurvedic medicine approved by the Centre, will be in place from Thursday onwards. Several citizens across the city with such symptoms can avail this free of cost.
The Union government has announced free distribution of Ayush-64 kits at
National Institute of Naturopathy in the city from Thursday. This particular announcement is made at a time when the nation is dealing with a massive surge in COVID-19 cases. The same will be available free of cost between 10 am and 5 pm.
Industry > Industry monitor > Healthcare
29 April 2021
Ayush 64, a poly-herbal preparation originally developed by the Central Council for Research in Ayurvedic Sciences (CCRAS) for the treatment of Malaria, in the year 1980 and now repurposed for the treatment Covid-19, has been found to be useful in the treatment of asymptomatic, mild and moderate Covid-19 infection as an adjunct to standard care.
Ministry of Ayush and the Council of Scientific and Industrial Research (CSIR) recently collaborated for robust multi-centre clinical trials to evaluate the safety and efficacy of Ayush 64 in the management of mild to moderate Covid-19 patients.
Clinical trials were conducted at KGMU, Lucknow; DMIMS, Wardha and BMC Covid Centre, Mumbai, involving 70 participants in each arm. Dr Chopra said Ayush 64 as an adjunct to standard of care (SoC) showed significant improvement and thus lesser period of hospitalisation compared to the only SoC procedure, Dr Arvind Chopra, director, Centre for R
DCGI approves DRDO-developed anti-Covid oral drug, could reduce supplemental oxygen dependence
With no fixed therapeutic regimen to treat COVID-19, the stand on drugs recommended for the treatment of the SARS-CoV-2 infection has witnessed see-sawing since 2020. Now, the World Health Organization (WHO) has stated that it does not recommend the use of Ivermectin, a commonly prescribed and inexpensive anti-parasitic drug, for the treatment of the viral disease.
Dr. Soumya Swaminathan, Chief Scientist at WHO, tweeted on Tuesday, stating that the international health body recommended against the use of Ivermectin for treating COVID-19 patients (with the exception of clinical trials). The tweet comes at a time when several countries, and also many states in India, have approved the use of the drug for treating the respiratory illness.